NEW YORK, July 17, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ : ZIOP ), Novavax Inc. (NASDAQ : NVAX ), Galena Biopharma Inc. (NASDAQ : GALE ), Sorrento Therapeutics Inc. (NASDAQ : SRNE ), and Aegerion Pharmaceuticals Inc. (NASDAQ : AEGR ). Free research report on ZIOPHARM Oncology can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ZIOP On Thursday, July 16, 2015, the NASDAQ Composite ended at 5,163.18, up 1.26%, the Dow Jones Industrial Average advanced 0.39%, to finish the day at 18,120.25, and the S&P 500 closed at 2,124.29, up 0.80%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
ZIOPHARM Oncology Inc.'s stock advanced 4.41%, to close the day at $13.02. The stock recorded a trading volume of 5.18 million shares, much above its three months average volume of 3.51 million shares. Over the last one month and over the past three months, ZIOPHARM Oncology Inc.'s shares have surged 18.47% and 8.95%, respectively. Furthermore, the stock has rallied 156.80% since the start of this year. The company's shares are trading 23.20% above their 50-day moving average and 62.67% above their 200-day moving average. Additionally, ZIOPHARM Oncology Inc. has a Relative Strength Index (RSI) of 66.09. Sign up and read the free notes on ZIOP at:
On Thursday, shares in Novavax Inc. recorded a trading volume of 4.01 million shares, higher than their three months average volume of 3.49 million shares. The stock ended the day 1.94% higher at $12.09. Novavax Inc.'s stock has gained 34.63% in the last one month, 46.90% in the previous three months and 103.88% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 25.77% and 60.42%, respectively. Furthermore, shares of Novavax Inc. have an RSI of 68.09. The complimentary notes on NVAX can be downloaded in PDF format at:
Galena Biopharma Inc.'s stock gained 2.81%, to close Thursday's session at $1.83. The stock recorded a trading volume of 2.15 million shares, below its three months average volume of 3.23 million shares. Over the previous three months and since the start of this year, Galena Biopharma Inc.'s shares have surged 27.97% and 21.19%, respectively. However, the stock has lost 1.61% in the last one month. The company is trading 9.86% and 8.88% above its 50-day and 200-day moving averages, respectively. Furthermore, Galena Biopharma Inc.'s stock has an RSI of 56.92. Register for free on Equity Research Institute and access the latest research on GALE at:
Sorrento Therapeutics Inc.'s stock finished Thursday's session 18.81% higher at $21.85. A total of 1.99 million shares were traded, which was above its three months average volume of 0.61 million shares. Over the last one month and the previous three months, Sorrento Therapeutics Inc.'s shares have surged 52.80% and 95.96%, respectively. Additionally, the stock has rallied 116.98% since the beginning of 2015. The company's shares are trading above their 50-day and 200-day moving averages by 49.27% and 116.15%, respectively. Sorrento Therapeutics Inc.'s stock has an RSI of 76.00. The complete research on SRNE is available for free at:
On Thursday, shares in Aegerion Pharmaceuticals Inc. ended the session 2.04% higher at $18.54. The stock reported a trading volume of 0.27 million shares, below its three months average volume of 0.59 million shares. Aegerion Pharmaceuticals Inc.'s shares have lost 1.59% in the last one month, 28.83% in the previous three months and 11.46% on YTD basis. The company is trading 3.95% below its 50-day moving average and 22.42% below its 200-day moving average. Moreover, shares of Aegerion Pharmaceuticals Inc. have an RSI of 49.55. Free in-depth research on AEGR is available at:
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
ERI has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.
ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.